Search

Your search keyword '"Guerra, Tommaso"' showing total 20 results
Start Over Author "Guerra, Tommaso"
20 results on '"Guerra, Tommaso"'

1. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis

Author

Simone, Marta, Lucisano, Giuseppe, Guerra, Tommaso, Paolicelli, Damiano, Rocca, Maria A., Brescia Morra, Vincenzo, Patti, Francesco, Annovazzi, Pietro, Gasperini, Claudio, De Luca, Giovanna, Ferraro, Diana, Margari, Lucia, Granella, Franco, Pozzilli, Carlo, Romano, Silvia, Perini, Paola, Bergamaschi, Roberto, Coniglio, Maria Gabriella, Lus, Giacomo, Vianello, Marika, Lugaresi, Alessandra, Portaccio, Emilio, Filippi, Massimo, Amato, Maria Pia, and Iaffaldano, Pietro

Published
2024
Full Text
View/download PDF

2. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

Author

Iaffaldano, Pietro, Lucisano, Giuseppe, Guerra, Tommaso, Patti, Francesco, Cocco, Eleonora, De Luca, Giovanna, Brescia Morra, Vincenzo, Pozzilli, Carlo, Zaffaroni, Mauro, Ferraro, Diana, Gasperini, Claudio, Salemi, Giuseppe, Bergamaschi, Roberto, Lus, Giacomo, Inglese, Matilde, Romano, Silvia, Bellantonio, Paolo, Di Monte, Elisabetta, Maniscalco, Giorgia Teresa, Conte, Antonella, Lugaresi, Alessandra, Vianello, Marika, Torri Clerici, Valentina Liliana Adriana, Di Sapio, Alessia, Pesci, Ilaria, Granella, Franco, Totaro, Rocco, Marfia, Girolama Alessandra, Danni, Maura Chiara, Cavalla, Paola, Valentino, Paola, Aguglia, Umberto, Montepietra, Sara, Ferraro, Elisabetta, Protti, Alessandra, Spitaleri, Daniele, Avolio, Carlo, De Riz, Milena, Maimone, Davide, Cavaletti, Guido, Gazzola, Paola, Tedeschi, Gioacchino, Sessa, Maria, Rovaris, Marco, Di Palma, Franco, Gatto, Maurizia, Cargnelutti, Daniela, De Robertis̄, Francesca, Logullo, Francesco Ottavio, Rini, Augusto, Meucci, Giuseppe, Ardito, Bonaventura, Banfi, Paola, Nasuelli, Davide, Paolicelli, Damiano, Rocca, Maria Assunta, Portaccio, Emilio, Chisari, Clara Grazia, Fenu, Giuseppe, Onofrj, Marco, Carotenuto, Antonio, Ruggieri, Serena, Tortorella, Carla, Ragonese, Paolo, Nica, Mihaela, Amato, Maria Pia, Filippi, Massimo, and Trojano, Maria

Published
2024
Full Text
View/download PDF

6. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.

Author

Iaffaldano, Pietro, Lucisano, Giuseppe, Guerra, Tommaso, Paolicelli, Damiano, Portaccio, Emilio, Inglese, Matilde, Foschi, Matteo, Patti, Francesco, Granella, Franco, Romano, Silvia, Cavalla, Paola, De Luca, Giovanna, Gallo, Paolo, Bellantonio, Paolo, Gallo, Antonio, Montepietra, Sara, Di Sapio, Alessia, Vianello, Marika, Quatrale, Rocco, and Spitaleri, Daniele

Subjects
PROPORTIONAL hazards models, NATALIZUMAB, MULTIPLE sclerosis, DISEASE progression
Abstract

Objective: No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse‐associated worsening (RAW) events are currently available. We aimed to compare the risk of achieving first 6 months confirmed PIRA and RAW events and irreversible Expanded Disability Status Scale (EDSS) 4.0 and 6.0 in a cohort of naïve patients treated with natalizumab or ocrelizumab from the Italian Multiple Sclerosis Register. Methods: Patients with a first visit within 1 year from onset, treated with natalizumab or ocrelizumab, and ≥3 visits were extracted. Pairwise propensity score‐matched analyses were performed. Risk of reaching the first PIRA, RAW, and EDSS 4.0 and 6.0 events were estimated using multivariable Cox proportional hazards models. Kaplan–Meier curves were used to show cumulative probabilities of reaching outcomes. Results: In total, 770 subjects were included (natalizumab = 568; ocrelizumab = 212) and the propensity score‐matching retrieved 195 pairs. No RAW events were found in natalizumab group and only 1 was reported in ocrelizumab group. A first PIRA event was reached by 23 natalizumab and 25 ocrelizumab exposed patients; 7 natalizumab‐ and 10 ocrelizumab‐treated patients obtained an irreversible EDSS 4.0, while 13 natalizumab‐ and 15 ocrelizumab‐treated patients reached an irreversible EDSS 6.0. No differences between the two groups were found in the risk (HR, 95%CI) of reaching a first PIRA (1.04, 0.59–1.84; p = 0.88) event, an irreversible EDSS 4.0 (1.23, 0.57–2.66; p = 0.60) and 6.0 (0.93, 0.32–2.68; p = 0.89). Interpretation: Both medications strongly suppress RAW events and, in the short term, the risk of achieving PIRA events, EDSS 4.0 and 6.0 milestones is not significantly different. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Multiple Sclerosis Progression and Relapse Activity in Children.

Author

Iaffaldano, Pietro, Portaccio, Emilio, Lucisano, Giuseppe, Simone, Marta, Manni, Alessia, Guerra, Tommaso, Paolicelli, Damiano, Betti, Matteo, De Meo, Ermelinda, Pastò, Luisa, Razzolini, Lorenzo, Rocca, Maria A., Ferrè, Laura, Brescia Morra, Vincenzo, Patti, Francesco, Zaffaroni, Mauro, Gasperini, Claudio, De Luca, Giovanna, Ferraro, Diana, and Granella, Franco

Published
2024
Full Text
View/download PDF

8. Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients

Author

Paolicelli, Damiano, primary, Ruggieri, Maddalena, additional, Manni, Alessia, additional, Gargano, Concetta D., additional, Carleo, Graziana, additional, Palazzo, Claudia, additional, Iaffaldano, Antonio, additional, Bollo, Luca, additional, Guerra, Tommaso, additional, Saracino, Annalisa, additional, Frigeri, Antonio, additional, Iaffaldano, Pietro, additional, and Trojano, Maria, additional

Published
2022
Full Text
View/download PDF

10. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register

Author

Iaffaldano, Pietro, primary, Lucisano, Giuseppe, additional, Guerra, Tommaso, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Brescia Morra, Vincenzo, additional, Zaffaroni, Mauro, additional, Pozzilli, Carlo, additional, Cocco, Eleonora, additional, Sola, Patrizia, additional, Salemi, Giuseppe, additional, Inglese, Matilde, additional, Bergamaschi, Roberto, additional, Gasperini, Claudio, additional, Conte, Antonella, additional, Salvetti, Marco, additional, Lus, Giacomo, additional, Maniscalco, Giorgia Teresa, additional, Totaro, Rocco, additional, Vianello, Marika, additional, Granella, Franco, additional, Ferraro, Elisabetta, additional, Aguglia, Umberto, additional, Gatto, Maurizia, additional, Sangalli, Francesca, additional, Chisari, Clara Grazia, additional, De Luca, Giovanna, additional, Carotenuto, Antonio, additional, Baroncini, Damiano, additional, Colombo, Delia, additional, Nica, Mihaela, additional, Paolicelli, Damiano, additional, Comi, Giancarlo, additional, Filippi, Massimo, additional, Amato, Maria Pia, additional, and Trojano, Maria, additional

Published
2022
Full Text
View/download PDF

11. The role of serum neurofilament light chain in an adult cohort of patients with acquired demyelinating syndromes of the central nervous system (P2-4.006)

Author

Bollo, Luca, primary, Iaffaldano, Pietro, additional, Ruggieri, Maddalena, additional, Palazzo, Claudia, additional, Mastrapasqua, Mariangela, additional, Caputo, Francesca, additional, Guerra, Tommaso, additional, Manni, Alessia, additional, Paolicelli, Damiano, additional, Simone, Marta, additional, Frigeri, Antonio, additional, and Trojano, Maria, additional

Published
2022
Full Text
View/download PDF

18. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register

Author

Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Francesco Patti, Marco Onofrj, Vincenzo Brescia Morra, Mauro Zaffaroni, Carlo Pozzilli, Eleonora Cocco, Patrizia Sola, Giuseppe Salemi, Matilde Inglese, Roberto Bergamaschi, Claudio Gasperini, Antonella Conte, Marco Salvetti, Giacomo Lus, Giorgia Teresa Maniscalco, Rocco Totaro, Marika Vianello, Franco Granella, Elisabetta Ferraro, Umberto Aguglia, Maurizia Gatto, Francesca Sangalli, Clara Grazia Chisari, Giovanna De Luca, Antonio Carotenuto, Damiano Baroncini, Delia Colombo, Mihaela Nica, Damiano Paolicelli, Giancarlo Comi, Massimo Filippi, Maria Pia Amato, Maria Trojano, Iaffaldano, Pietro, Lucisano, Giuseppe, Guerra, Tommaso, Patti, Francesco, Onofrj, Marco, Brescia Morra, Vincenzo, Zaffaroni, Mauro, Pozzilli, Carlo, Cocco, Eleonora, Sola, Patrizia, Salemi, Giuseppe, Inglese, Matilde, Bergamaschi, Roberto, Gasperini, Claudio, Conte, Antonella, Salvetti, Marco, Lus, Giacomo, Maniscalco, Giorgia Teresa, Totaro, Rocco, Vianello, Marika, Granella, Franco, Ferraro, Elisabetta, Aguglia, Umberto, Gatto, Maurizia, Sangalli, Francesca, Chisari, Clara Grazia, De Luca, Giovanna, Carotenuto, Antonio, Baroncini, Damiano, Colombo, Delia, Nica, Mihaela, Paolicelli, Damiano, Comi, Giancarlo, Filippi, Massimo, Amato, Maria Pia, and Trojano, Maria

Subjects
Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple sclerosis, Multiple Sclerosis, Relapsing-Remitting, Neurology, big data, Area Under Curve, data-driven algorithm, disease registry, secondary progressive, Humans, Settore MED/26 - Neurologia, Neurology (clinical), prognosis
Abstract

Background: Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available. Objectives: To compare diagnostic performances of two different data-driven SPMS definitions. Methods: Data-driven SPMS definitions based on a version of Lorscheider’s algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist’s definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC). Results: A cohort of 10,240 MS patients with ⩾5 years of follow-up was extracted from the Italian MS Registry; 880 (8.5%) patients were classified as SPMS according to the neurologist definition, 1806 (17.6%) applying the DDA and 1134 (11.0%) with the EXPAND definition. The DDA showed greater discrimination power (AUC: 0.8 vs 0.6) and a higher sensitivity (77.1% vs 38.0%) than the EXPAND definition, with similar specificity (88.0% vs 91.5%). PPV and NPV were higher using the DDA than considering EXPAND definition (37.5% vs 29.5%; 97.6% vs 94.0%). Conclusion: Data-driven definitions demonstrated greater ability to capture SP transition than neurologist’s definition and the global accuracy of DDA seems to be higher than the EXPAND definition.

Published
2022

19. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.

Author

Iaffaldano P, Lucisano G, Guerra T, Patti F, Onofrj M, Brescia Morra V, Zaffaroni M, Pozzilli C, Cocco E, Sola P, Salemi G, Inglese M, Bergamaschi R, Gasperini C, Conte A, Salvetti M, Lus G, Maniscalco GT, Totaro R, Vianello M, Granella F, Ferraro E, Aguglia U, Gatto M, Sangalli F, Chisari CG, De Luca G, Carotenuto A, Baroncini D, Colombo D, Nica M, Paolicelli D, Comi G, Filippi M, Amato MP, and Trojano M

Subjects
Humans, Area Under Curve, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive diagnosis, Multiple Sclerosis, Relapsing-Remitting diagnosis
Abstract

Background: Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available., Objectives: To compare diagnostic performances of two different data-driven SPMS definitions., Methods: Data-driven SPMS definitions based on a version of Lorscheider's algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist's definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC)., Results: A cohort of 10,240 MS patients with ⩾5 years of follow-up was extracted from the Italian MS Registry; 880 (8.5%) patients were classified as SPMS according to the neurologist definition, 1806 (17.6%) applying the DDA and 1134 (11.0%) with the EXPAND definition. The DDA showed greater discrimination power (AUC: 0.8 vs 0.6) and a higher sensitivity (77.1% vs 38.0%) than the EXPAND definition, with similar specificity (88.0% vs 91.5%). PPV and NPV were higher using the DDA than considering EXPAND definition (37.5% vs 29.5%; 97.6% vs 94.0%)., Conclusion: Data-driven definitions demonstrated greater ability to capture SP transition than neurologist's definition and the global accuracy of DDA seems to be higher than the EXPAND definition.

Published
2022
Full Text
View/download PDF

20. Dengue fever in a multiple sclerosis patient taking Ocrelizumab.

Author

Guerra T, Bollo L, Trojano M, and Iaffaldano P

Subjects
Antibodies, Monoclonal, Humanized adverse effects, Humans, Immunologic Factors adverse effects, Dengue complications, Dengue drug therapy, Multiple Sclerosis drug therapy, Multiple Sclerosis, Relapsing-Remitting drug therapy
Abstract

Dengue fever (DF) is an endemic infectious disease in tropical and subtropical regions. Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen on B cells, which is approved for the treatment of both relapsing-remitting multiple sclerosis (RRMS) and primary-progressive multiple sclerosis (PPMS). We describe the favorable clinical outcome of DF in an RRMS patient treated with Ocrelizumab, who neither presented hemorrhagic or systemic shock symptoms nor reported neurological worsening.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results